With this massive pullback, no news and their competition $AMAG floating around $10. I expect to see $PTN contest it's 4.76 resistance over the next 4-6 weeks.
Will Women get an F&DA approval for their VIAGRA?? Good entry with LT target 4-5 if approved.
This chart is for own use. Viewers come to own conclusions and appreciate comments and learning thoughts.
I see the beauty in this chart, the moving avreages aline with my technical analysis on the daily that this is a pretty obvious short, have buy orders at .95 and then perhaps at .75 for a easy profit long term investment in the making. They will either touch, go up, then come back down before a nice impulse. Happy trading.
Earlier this year i picked up some $PTN at .41
took from some of my port's losers to throw more at this big winner.
Getting some respect of the 50% fib here; As y'all know the concept of 50% is critical to ichimoku, HA candles, etc.
Also getting some bullish jpn candlestick patterns with volume trending in that dir. via OBV and Volume Trend Accumulation...
Entered @ .39 as a prospect breakout. Upward trends are strong with profitable volatility, proves to be an excellent trading vehicle at the moment. RSI resting on trend line tells me tomorrow should be interesting.
Tight trailing stops as always.
Very close to 52w HIGH.
Looks like it has a BIG resistance @ those lvls.
Tomorrow gonna be ride or die.
Long if break 0.86
Short if Can't break 0.86 & can't hold 0.80
PTN seems going for more upside. If it fails breaking the level posted on chart i'm looking for a short setup. A strong breakout of that level can invalidate this setup.
A familiar theme as of late. The chart is self-explanatory, depicting a violated lower trend line and corresponding support levels (S-1 - S-4). In the event the stock closes below that psychological $1.00 mark, selling will likely accelerate. For reference only. As always, these are only my opinions and not investment advice.
Palatin Technologies, Inc. is a biopharmaceutical company. The Company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. The Company's primary product in clinical development is bremelanotide for the treatment of premenopausal women with hypoactive sexual desire disorder (HSDD), which is a type of female sexual dysfunction (FSD) defined as low desire with associated distress. Its other drug development programs include Melanocortin receptor-4 (MC4r), PL-3994 and Melanocortin receptor-1 (MC1r). MC4r is a compound used for treatment of obesity and diabetes. PL-3994 is a subcutaneously injected guanylate-cyclase type A (GC-A) receptor agonist. MC1r agonist peptides are used for treatment of inflammatory and dermatologic disease indications.
This website uses cookies to ensure you get the best experience on our website. To learn more about cookies, including how to control cookies, please read our Cookies Policy.
PTN
